Delving into the Latest Updates on Doppel Farmaceutici SRL with Synapse

概览

关联

1

项与 Doppel Farmaceutici SRL 相关的临床试验

NCT03238534

/ Completed临床4期

Relief of Heartburn and Epigastric Pain Comparing Neobianacid® With Omeprazole: a Randomized, Double Blind, Double Dummy, Reference Product Controlled, Parallel Group, Non-inferiority Clinical Study

Comparison of Neobianacid® clinical efficacy to omeprazole in relief of heartburn or epigastric pain

开始日期2017-09-12

申办/合作机构

Aboca S.p.A. Società Agricola

[+3]

100 项与 Doppel Farmaceutici SRL 相关的临床结果

登录后查看更多信息

0 项与 Doppel Farmaceutici SRL 相关的专利（医药）

登录后查看更多信息

1

项与 Doppel Farmaceutici SRL 相关的新闻（医药）

2025-04-14

·ETPharma

Zydus muscular dystrophy drug receives FDA final approval

Ahmedabad: Indian drug maker Zydus Lifesciences has received final approval from the United States Food and Drug Administration (US FDA) to manufacture Jaythari ( Deflazacort ) tablets, indicated for the treatment of Duchenne muscular dystrophy . The approved drug ‘Deflazacort’ is a corticosteroid indicated for the treatment of a rare disorder of the Central Nervous System (CNS) called Duchenne muscular dystrophy (DMD) in patients 5 years of age and older and is a reference listed equivalent of Emflaza. As per Zydus release the drug will be manufactured at its Italy facility n Doppel Farmaceutici S.r.l Post this approval the Indian drug maker now has 424 approvals and has so far filed 492 ANDAs since the commencement of the filing process in FY 2003-04. By Online Bureau ,